Rapport Therapeutics, a young biotech company with technology from the labs of Johnson & Johnson, is now preparing to enter the public markets to finance clinical research for a lead program that could help patients whose epilepsy doesn’t respond to currently available anti-seizure medications.

Rapport Therapeutics是一家年轻的生物技术公司，拥有强生实验室的技术，目前正准备进入公共市场，为一项领先项目的临床研究提供资金，该项目可以帮助癫痫患者对目前可用的抗癫痫药物无反应。

Rapport’s IPO paperwork filed with securities regulators late Friday does not yet specify how many shares it plans to offer and in what price range. IPO research firm Renaissance Capital has penciled in a $100 million placeholder figure for the proposed stock offering. The biotech company, which is headquartered in Boston and maintains additional office and lab space in San Diego, has applied to list shares on the Nasdaq under the stock symbol “RAPP.”.

Rapport周五晚些时候向证券监管机构提交的首次公开募股文件尚未明确计划发行多少股票以及价格区间。IPO研究公司复兴资本（Renaissance Capital）为拟议的股票发行画出了一个1亿美元的占位符。这家总部位于波士顿、在圣地亚哥拥有额外办公室和实验室的生物技术公司已申请在纳斯达克（Nasdaq）以股票代码“RAPP”上市。

Of the estimated 3 million adults in the U.S. who suffer from epilepsy, about 1.8 million have focal epilepsy, Rapport said in its IPO filing. In this form of epilepsy, seizures are caused by intermittent abnormal electrical activity in specific areas of the brain. The AMPA receptor is a clinically validated epilepsy target addressed by some currently available epilepsy drugs.

Rapport在首次公开募股文件中表示，据估计，美国有300万成年人患有癫痫病，其中约180万人患有局灶性癫痫病。在这种形式的癫痫中，癫痫发作是由大脑特定区域的间歇性异常电活动引起的。AMPA受体是一些目前可用的癫痫药物所解决的临床验证的癫痫靶标。

But these anti-seizure medications bind to AMPA receptors throughout the brain, which contributes to side effects that are unrelated to epilepsy, such as cognitive impairment, sedation, lack of muscle coordination, and dizziness, Rapport said in its IPO filing..

但是这些抗癫痫药物与整个大脑中的AMPA受体结合，这会导致与癫痫无关的副作用，如认知障碍、镇静、肌肉协调不足和头晕，拉普拉特在其首次公开募股文件中表示。。

Sponsored Post

赞助帖子

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

随着人工智能的兴起，医疗保健领域可能会出现哪些知识产权纠纷？

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Munck Wilson Mandala合伙人格雷格·豪森（GregHowison）在回答电子邮件中提出的问题时，分享了他对人工智能、IP、连接设备及其产生的数据产生的一些法律后果的看法。

The research of Rapport focuses on receptor-associated proteins (RAPs), which play a key role in regulating receptor expression and function. Lead program RAP-219 is designed to selectively target a neuronal RAP for the AMPA receptor. This RAP, TARP gamma-8 RAP, is found only in certain regions, such as the hippocampus, which is involved in focal epilepsy, the company said in the filing.

密切关系的研究集中在受体相关蛋白（RAPs）上，它在调节受体的表达和功能中起着关键作用。领导程序RAP-219旨在选择性靶向AMPA受体的神经元RAP。该公司在文件中表示，这种RAP，TARPγ-8 RAP，仅在某些区域发现，如海马，这与局灶性癫痫有关。

In a Phase 1 study enrolling healthy volunteers, Rapport reported its TARP gamma-8 RAP-targeting drug was well tolerated with results that support once-daily oral dosing..

在一项招募健康志愿者的第一阶段研究中，Rapport报告称其TARPγ-8 RAP靶向药物耐受性良好，结果支持每日一次口服给药。。

“We believe that RAP-219, as compared to currently available [anti-seizure medications], has the potential to have a greater therapeutic index, meaning a wider range of doses at which it is likely to be effective without causing unacceptable [adverse effects],” Rapport said in its filing. “If RAP-219 is approved, this could have important clinical utility for the management of focal epilepsy.”.

“我们认为，与目前可用的[抗癫痫药物]相比，RAP-219有可能具有更大的治疗指数，这意味着它可能有效的剂量范围更广，而不会产生不可接受的[不良反应]，”拉普勒在其文件中表示。“如果RAP-219获得批准，这可能对局灶性癫痫的治疗具有重要的临床实用性。”。

Rapport is now planning a Phase 2a study enrolling patients with drug-resistant focal epilepsy. The company plans to begin the study in the middle of this year; preliminary data are expected in mid-2025. Rapport believes targeting TARP gamma-8 could also treat peripheral neuropathic pain and bipolar disorder.

Rapport目前正在计划一项2a期研究，招募耐药性局灶性癫痫患者。该公司计划在今年年中开始这项研究；初步数据预计将于2025年年中发布。拉普特认为，靶向TARPγ-8也可以治疗周围神经性疼痛和双相情感障碍。

Additional Phase 2a tests for both indications are planned for later this year and in 2025. Rapport’s research has also identified a different molecule that addresses TARP gamma-8 while offering different chemical and pharmacokinetic properties. This molecule, named RAP-199, is on track for a Phase 1 study planned for the first half of 2025..

计划在今年晚些时候和2025年对这两种适应症进行额外的2a期测试。Rapport的研究还发现了一种不同的分子，它可以解决TARPγ-8的问题，同时提供不同的化学和药代动力学特性。该分子命名为RAP-199，计划于2025年上半年进行第一阶段研究。。

The RAP technology platform has yielded drug candidates for other targets. Rapport has discovery-stage research addressing the nicotine acetylcholine receptor (nAChR). One program for this target is in development for chronic pain and another program is for hearing disorders.

RAP技术平台已经为其他目标产生了候选药物。Rapport拥有针对尼古丁乙酰胆碱受体（nAChR）的发现阶段研究。针对这一目标的一个计划正在开发中，用于治疗慢性疼痛，另一个计划用于治疗听力障碍。

sponsored content

推广内容

A Deep-dive Into Specialty Pharma

深入研究专业制药

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS. .

特种药物是一类用于治疗复杂、慢性或罕见疾病的处方药。虽然这种分类最初是为了定义罕见病（也称为“孤儿”疾病）的治疗方法，但在美国影响不到20万人，最近，特种药物已成为治疗癌症，自身免疫性疾病，糖尿病，丙型肝炎和艾滋病毒/艾滋病等慢性和复杂疾病的基石。

By

签字人

PurpleLab

PurpleLab

Rapport is based on the discoveries of David Bredt, the company’s scientific founder and chief scientific officer. The filing states Bredt pioneered the targeting of RAPs with small molecules in executive roles at Johnson & Johnson subsidiary Janssen Pharmaceutica and Eli Lilly, as well as an earlier role as a professor of physiology at the University of California, San Francisco.

融洽的关系是基于该公司的科学创始人兼首席科学官大卫·布雷特的发现。备案州布雷特率先在强生公司子公司杨森制药公司（JanssenPharmaceutica）和礼来公司（Eli Lilly）担任执行职务，并在加利福尼亚大学旧金山分校（University of California，San Francisco）担任生理学教授。

Rapport’s employee roster includes scientists who worked on the RAP platform at Janssen..

Rapport的员工名单中包括在Janssen的RAP平台上工作的科学家。。

Rapport formed in 2022 with support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC, the investment arm of J&J. The company licensed certain RAP programs from Janssen, including lead drug candidate RAP-219 as well as other assets stemming from the research of Bredt and his Janssen colleagues.

拉近关系于2022年在第三摇滚风险投资公司和强生创新JJDC（强生公司的投资部门）的支持下形成。该公司从杨森获得了某些RAP项目的许可，包括主要候选药物RAP-219以及来自布雷特及其杨森同事研究的其他资产。

Rapport’s CEO is Abraham Ceesay, whose experience includes serving as president of Cerevel Therapeutics, a neuroscience drug developer that is being acquired by AbbVie..

Rapport的首席执行官是AbrahamCeesay，他的经验包括担任Cerevel Therapeutics总裁，这是一家神经科学药物开发公司，正在被AbbVie收购。。

Since its founding, Rapport has raised about $250 million from investors, according to the filing. The most recent capital raise was a $150 million Series B financing last August that turned out to be a crossover round, the type of financing that includes firms that invest in both public and private companies and signals a coming IPO.

文件显示，自成立以来，Rapport已从投资者那里筹集了约2.5亿美元。最近的一次融资是去年8月进行的1.5亿美元的B轮融资，结果是一轮交叉融资，这种融资类型包括投资于上市公司和私人公司的公司，并预示着即将进行IPO。

Cormorant Asset Management led the round and is one of Rapport’s largest shareholders, though the filing does not yet specify how big of a stake it owns. Other large shareholders in Rapport include Arch Venture Partners, Johnson & Johnson Innovation-JJDC, and Fidelity..

鸬鹚资产管理公司（Cormorant Asset Management）领导了这一轮交易，并且是Rapport的最大股东之一，尽管该文件尚未具体说明其持有的股份有多大。其他关系融洽的大股东包括Arch Venture Partners、Johnson&Johnson Innovation JJDC和Fidelity。。

At the time of the funding announcement, executives told MedCity News that the financing extended Rapport’s cash runway into 2027. As of the end of the first quarter of this year, the company reported a cash position of $74.3 million and short-term investments totaling $119 million. According to the prospectus, a yet-to-be-determined amount of the IPO proceeds will go toward Phase 2a development of RAP-219, including proof-of-concept trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder.

在宣布融资时，高管们告诉MedCity News，融资将Rapport的现金跑道延长至2027年。截至今年第一季度末，该公司报告的现金头寸为7430万美元，短期投资总额为1.19亿美元。根据招股说明书，尚未确定的IPO收益将用于RAP-219的2a期开发，包括局灶性癫痫，周围神经性疼痛和双相情感障碍的概念验证试验。

An unspecified sum will also be used for Phase 1 testing of a long-acting injectable form of RAP-219, as well as early clinical development of RAP-199..

未指明的金额也将用于长效注射型RAP-219的第一阶段测试，以及RAP-199的早期临床开发。。

Image: Getty Images, Iaremenko

图片：Getty Images，Iaremenko

Topics

主题

biopharma nl

生物制药

Boston

波士顿

Clinical Trials

临床试验

Epilepsy

癫痫

Johnson & Johnson

强生公司

Rapport Therapeutics

融洽疗法

MedCity News Daily Newsletter

MedCity新闻每日通讯

Sign up and get the latest news in your inbox.

注册并在收件箱中获取最新消息。

Enter your email address

输入您的电子邮件地址

Subscribe Now

立即订阅

We will never sell or share your information without your consent. See our privacy policy.

未经您同意，我们绝不出售或共享您的信息。请参阅我们的隐私政策。